Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DERM vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Captures Overall Composite Edge (36.8 SELL vs 40.9 SELL), While DERM Leads 4–2 on Growth & Valuation Pillars

BOLD Overall Winner 6-Pillar Tally: DERM 4 – 2 BOLD Matrix Metrics: DERM 6 – 4 BOLD

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. DERM trades at $3.30 (8.3x Forward P/E, -2.9% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY).
  • Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both DERM (40.9/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: DERM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DERM vs BOLD
DERM NASDAQ
Journey Medical Corporation Common Stock
Pharmaceutical Preparations
$3.30
-7.04% 1D
Market Cap $100.2M
TTM Revenue $70M
Forward P/E 8.3x
Beta / 30D Vol 2.08β · 77% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 72.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 25
RSI-14: 25.0 · SMA20: $4.44 · SMA50: $5.50
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (DERM 4 – 2 BOLD)

Columns: Metric · DERM · BOLD
1. Valuation Multiples DERM
Forward P/E 8.3x N/M
Trailing P/E 17.6x N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x N/M
2. Growth & Scale DERM
Revenue Growth (YoY) +7.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $70M N/A
Market Cap $100.2M $56.2M
3. Profitability & Quality BOLD
Gross Margin 65.9% N/A
Operating Margin -2.9% 0.0%
Net Profit Margin -7.3% 0.0%
Return on Equity (ROE) -17.6% -64.6%
4. Balance Sheet & Cash Flow DERM
Cash Generation (TTM) -$8.5M -$48M
Cash Flow Margin -12.3% N/A
Net Cash / Leverage $3.3M Net Debt (0.79x D/E) $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BOLD
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 17.9% (4th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat DERM
OpEx & R&D Intensity 68.8% of Rev ($48M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DERM (6) vs BOLD (4)
Institutional Metric DERM BOLD Criterion Row Edge
Market Capitalization
Scale
$100.2M $56.2M Larger Scale DERM
Trailing P/E Ratio
Valuation
17.6x N/M Lower Multiple DERM
Forward P/E Ratio
Valuation
8.3x N/M Lower Multiple DERM
Revenue Growth (YoY)
Growth
+7.6% +0.0% Higher Growth DERM
Operating Margin (TTM)
Profitability
-2.9% 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
-7.3% 0.0% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-17.6% -64.6% Higher ROE DERM
52-Week Range Position
Momentum
1% ($3–$10) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
2.08β · 77% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite DERM
Trailing 12M Revenue (USD)
Operating Scale
$70M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.5M ($3.3M Net Debt (0.79x D/E)) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +30.25 pp
DERM: -35.17% · BOLD: -4.92%
3M Horizon BOLD +36.66 pp
DERM: -58.28% · BOLD: -21.62%
6M Horizon BOLD +105.74 pp
DERM: -44.63% · BOLD: +61.11%
1Y Horizon BOLD +158.6 pp
DERM: -56.86% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DERM vs BOLD. Trailing 12-month operating profitability (DERM -2.9% vs BOLD 0.0%) and valuation multiples (DERM 8.3x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DERM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$70M
Gross Margin65.9%
Op. Margin-2.9%
ROE / Fwd P/E-17.6% · 8.3x
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DERM BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 17.9%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DERM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DERM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $100.2M market capitalization and -2.9% operating margin.
OpEx & R&D Reinvestment 68.8% of Rev ($48M)
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DERM vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. DERM trades at $3.30 (8.3x Forward P/E, -2.9% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both DERM (40.9/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: DERM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DERM leads the Growth & Scale pillar: DERM posts +7.6% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (65.9% gross margin, -2.9% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DERM generates $70M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, DERM deploys 68.8% of Rev ($48M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

DERM screens cheaper on headline valuation multiples. DERM trades at 8.3x Forward P/E, 17.6x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-12.3% FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DERM (-17.6% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DERM carries 17.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.08β · 77% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.